Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience-Reference-Cited by-同舟云学术

Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience

Published:2019-02 Issue:1 Volume:29 Page:16-32
ISSN:2159-3337
Container-title:Nucleic Acid Therapeutics
language:en
Short-container-title:Nucleic Acid Therapeutics

Author:

Crooke Stanley T.¹,Baker Brenda F.¹,Xia Shuting¹,Yu Rosie Z.¹,Viney Nicholas J.¹,Wang Yanfeng¹,Tsimikas Sotirios¹,Geary Richard S.¹

Affiliation:

1. Ionis Pharmaceuticals, Inc., Carlsbad, California.

Publisher

Mary Ann Liebert Inc

Subject

Drug Discovery,Genetics,Molecular Biology,Molecular Medicine,Biochemistry

Link

https://www.liebertpub.com/doi/pdf/10.1089/nat.2018.0753

Reference48 articles.

1. RNA-Targeted Therapeutics

2. Pharmacology of Antisense Drugs

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside;Cancers;2024-08-23

2. Genotypic and phenotypic analysis of 173 patients with extremely rare pathogenic mutations who applied for experimental antisense oligonucleotide treatment;2024-08-06

3. Efficacy and Safety of Donidalorsen for Hereditary Angioedema;New England Journal of Medicine;2024-07-04

4. A Randomized, Open-Label, Phase I, Single-Dose Study of Antisense Oligonucleotide, Vupanorsen, in Chinese Adults with Elevated Triglycerides;Drugs in R&D;2024-06

5. Hereditary angioedema: current therapeutic management and future approaches;Current Opinion in Allergy & Clinical Immunology;2024-05-13